Syngenta has expanded its commitment to agricultural biologicals through a new strategic cooperation with German biotechnology specialist BRAIN Biotech AG, giving the company access to advanced microbial strain engineering capabilities and one of Europe’s largest collections of microbial resources.
The agreement brings together Syngenta’s biologicals research operation and BRAIN Biotech’s expertise in synthetic biology, with the partners aiming to develop next-generation biological solutions designed to enhance plant health, resilience and productivity.
While major crop input companies have spent years screening naturally occurring microorganisms for potential agricultural applications, the collaboration highlights a broader industry shift towards optimising and engineering microbes to improve their commercial performance, scalability and consistency.
“At Syngenta, we believe agricultural innovation unlocks the next-generation of sustainable farming solutions and are committed to working with partners who share the same vision,” said Jérôme Cassayre, head of biologicals research at Syngenta. “We’re excited to work with BRAIN Biotech to push back the boundaries of science in agricultural biologicals.”
Access to vast microbial library
A key element of the partnership is access to the BRAIN Biotech BioArchive, a proprietary collection containing tens of thousands of microbial strains that can be screened for specific industrial and agricultural applications.
The company said its specialist capabilities include identifying, developing and optimising microbial strains for the production of enzymes and biomolecules, expertise now marketed under its BRAINBiocatalysts industrial biotechnology brand.
For Syngenta, the BioArchive could help accelerate the discovery of new biological candidates at a time when major crop input manufacturers are racing to expand portfolios spanning biostimulants, biological crop protection products and other nature-based technologies.
According to BRAIN Biotech, however, discovery is only one part of bringing a biological product to market.
“Microbial discovery is an important starting point, but identifying a promising microorganism is only part of the journey towards a commercially viable product,” a company spokesperson told AgNavigator. “The next challenge is to optimise it for reliable, efficient and scalable industrial production. This is where BRAINBiocatalysts expertise in strain development and synthetic biology comes into play.”
The spokesperson added that traits including process robustness, growth performance and production yields are important considerations when developing microbial products, although specific objectives depend on the intended application.
Product focus remains under wraps
Despite the strategic significance of the agreement, both companies are keeping details of the programme closely guarded.
Asked whether the collaboration would focus on biocontrols, biostimulants, nitrogen-fixing microbes, stress-tolerance solutions or other product categories, a BRAIN Biotech spokesperson said the partnership had been intentionally structured with a broad remit.
“Our collaboration is broadly focused on the development of innovative biological solutions for more sustainable agriculture,” the spokesperson said. “We have deliberately kept the scope open to allow us to explore different opportunities where BRAIN Biotech’s expertise can contribute to addressing agricultural challenges.”
The company declined to disclose specific product categories, target markets or development priorities.
Timelines and milestones yet to be defined
The announcement also provides little indication of when farmers or investors can expect products to emerge from the collaboration.
Asked about development milestones over the next three to five years and potential commercialisation timelines, BRAIN Biotech said it was too early to provide guidance.
“It is still too early to comment on specific development milestones or potential product launch dates,” the spokesperson said, noting that biological product development remains a complex, multi-stage process influenced by technical and regulatory requirements.
The company added that decisions related to downstream product development and commercialisation sit primarily within Syngenta’s remit.
